A single nucleotide mutation drastically increases the expression of tumor-homing NGR-TNFα in the *E. coli* M15-pQE30 system by improving gene transcription

Jie Chen1 · Hao Yang1,2,3 · Yanru Feng1 · Qiuxiao Shi1 · Zhao Li1 · Ze Tao1 · Jie Fan1 · Youmei Jin1 · Shengfu Li1 · Jingqiu Cheng1,2 · Xiaofeng Lu1,2,3

Received: 28 September 2020 / Revised: 12 January 2021 / Accepted: 20 January 2021

Abstract

Due to their potent immune stimulation, tumor necrosis factor alpha (TNFα) variants with tumor-homing activity are attractive as novel antitumor drugs. The promising antitumor effect of NGR-TNFα in clinical trials triggered extensive interest in developing novel tumor-homing TNFα variants in recent years. Owing to its promising antitumor effect, NGR-TNFα is usually used as a control for newly developed tumor-homing TNFα variants. In our previous works, we produced a pericyte-targeting Z-TNFα at high levels using the *Escherichia coli* (E. coli) M15-pQE30 system. To further compare Z-TNFα and NGR-TNFα, we attempted to express NGR-TNFα using the same system. Surprisingly, native NGR-TNFα was expressed at a low (~ 0.2 mg/L) level in *E. coli* M15 containing the pQE30 plasmid. However, a single nucleotide mutation of C to G, resulting in a substitution of leucine (L) with valine (V) at the start of TNFα, increased the expression of NGR-TNFα by ~ 100 times through improving transcription. In addition, the amino acid substitution showed a little impact on the receptor binding, in vitro cytotoxicity, and in vivo antitumor effect of NGR-TNFα. As fusing NGR to the N-terminus of TNFα with a valine substitution did not reduce the protein yield, the TNFα gene with a C > G mutation might be used to prepare novel tumor-homing TNFα when the native TNFα-based variant is expressed at an extremely low level in *E. coli*. Notably, in addition to the mutated valine, the impact of N-terminal additional amino acids provided by pQE30 vector on the function of TNFα variant must be carefully evaluated.

Key points

- A single nucleotide mutation increased the expression of NGR-TNFα by two orders.
- Nucleotide mutation-induced amino acid substitution did not reduce NGR-TNFα activity.

Keywords Tumor necrosis factor alpha · Tumor vasculature normalization · Nucleotide mutation · Recombinant expression · *Escherichia coli*

Introduction

Excessive angiogenesis is a pivotal characteristic in the tumor microenvironment to fuel malignant tumor growth and metastasis. To obtain sufficient oxygen and nutrients, overgrowing tumor cells frequently release pro-angiogenesis factors, which results in the formation of disorganized blood vessel networks in solid tumors (Lugano et al. 2020; Zuazo-Gaztelu and Casanovas 2018). Aberrant architecture, including dilation, tortuosity, and inadequate perivascular cell investment of the disorganized tumor vascular system, induce high permeability of tumor blood vessels, which further induces elevated interstitial fluid pressure, thus causing poor perfusion of antitumor agents into the tumor parenchyma (Viallard and Larrivee...
Extensive interest in the development of novel TNF-α vessel normalization inducers (Curnis et al. 2004; Fan et al. 2017). Compared to vasculature disruption, vessel normalization has been found to be more efficient at improving the blood perfusion and tumor-targeted delivery of antitumor agents (Huang et al. 2018; Viallard and Larriève 2017). In fact, anti-angiogenesis mediated by vascular endothelial growth factor (VEGF)-neutralizing antibodies or VEGF receptor blockers makes the tumor blood vessels more similar to normal blood vessels in structure and function, an observation designated as vessel normalization. Compared to disorganized tumor blood vessels, these normalized tumor blood vessels exert better blood perfusion and drug delivery, and this has led to a rapid progress in combining vessel normalization inducers and chemicals or radioactive substances for the treatment of solid tumors in recent years (Fan et al. 2019; Ho et al. 2019; Park et al. 2017).

Tumor necrosis factor alpha (TNF-α) is a homotrimeric cytokine exerting potent antitumor activities by binding to its cell surface receptors TNFRI and TNFR2. However, owing to its life-threatening systemic toxicity, recombinant TNFα is only approved in Europe to treat patients with limb-threatening soft tissue sarcoma via local perfusion (Balkwill 2009; Jakob and Hohenberger 2016). To reduce systemic toxicity, ligands recognizing tumor-associated endothelial cells or pericytes have been genetically conjugated to TNFα (Curnis et al. 2000; Fan et al. 2019; Johansson et al. 2012). Of these fusion proteins, NGR-TNFα was constructed by coupling the tumor-homing NGR peptide to TNFα. In addition to disrupting tumors at high doses, NGR-TNFα was found to induce vessel normalization by modulating endothelial cells at low doses, which facilitated the tumor-targeted delivery of chemotherapeutics, thus exerting a synergistic antitumor effect. Phase II/III clinical trials for advanced cancer treatment using a NGR-TNFα-based regimen triggered extensive interest in the development of novel TNFα-based vessel normalization inducers (Curnis et al. 2004; Fan et al. 2019; Johansson et al. 2012; Yuan et al. 2009). In our previous work, we developed a novel fusion protein Z-TNFα by conjugating a platelet-derived growth factor receptor β (PDGFRβ)-specific ZPDGFRβ affibody to TNFα. In contrast to NGR-TNFα acting on tumor-associated endothelial cells, Z-TNFα could modulate tumor-associated pericytes, thus inducing vessel normalization, which consequently improved chemotheraphy for solid tumors (Fan et al. 2019). The promising vessel normalization mediated by Z-TNFα triggered our interest in comparing Z-TNFα- and NGR-TNFα-based combination therapies for solid tumors. As Z-TNFα was produced by using pQE30 in E. coli M15 (Fan et al. 2019), considering the impact of the extra amino acid residuals introduced by the plasmid on the biological activity of TNFα, we attempted to prepare recombinant NGR-TNFα via the same expression system.

To construct NGR-TNFα, considering NGR (CNGRCG) is a small peptide, we decided to introduce NGR to the N-terminus of mouse TNFα by polymerase chain reaction (PCR) with a specific primer containing an NGR motif. After insertion into pQE30, the amplified gene encoding NGR-TNFα produced a recombinant protein at a high level similar to that of Z-TNFα. However, simultaneous sequence verification revealed that a cytosine (C) was changed to guanine (G) in the forward primer, which resulted in a substitution of the leucine (L) by valine (V) at the start of TNFα in NGR-TNFα. To avoid impact of the amino acid substitution on the biological activity of NGR-TNFα, we prepared the gene encoding native NGR-TNFα with leucine at the start of TNFα by chemical synthesis. In brief, the native NGR-TNFα with leucine at the start of TNFα was designated NGR-TNFα-L, while the mutated NGR-TNFα with valine at the start of TNFα was designated NGR-TNFα-V. We were surprised that the expression level of NGR-TNFα-L was substantially lower than that of NGR-TNFα-V in the same expression system, suggesting that the single nucleotide mutation altered the gene expression or solubility of the recombinant protein. This unusual phenomenon greatly triggered our interest in investigating the impact of a single nucleotide/amino acid mutation on the expression and biological activity of NGR-TNFα.

In this study, we compared the gene transcription, protein yield, and biological activity of NGR-TNFα-L and NGR-TNFα-V. The single nucleotide mutation that caused an amino acid substitution significantly increased the yield but had little impact on the biological activity of NGR-TNFα. Moreover, unlike fusion to TNFα-L, fusing NGR to TNFα-V did not reduce the yield of fusion proteins. These results suggested that the TNFα gene with a C > G mutation could be used to prepare novel tumor-homing TNFα variants that might be expressed at high levels in the E. coli M15-pQE30 system.

Materials and methods

Protein expression and purification

The gene encoding NGR-TNFα-V was amplified by PCR using the forward (5′-tcaggtctgcaagggcgttcg gctcgatcatctctcagaaatgcagta-3′) and reverse (5′- tcaggtctgcaagggcgttcg gctcgatcatctctcagaaatgcagta-3′) primer pairs with the murine TNFα gene in the pQE30 plasmid as a template (Fan et al. 2019). The primers were synthesized by GenScript (Nanjing, China), and the PCR product was subcloned into the pQE30 plasmid between BamHI I and Kpn I according to our previous protocol (Yang et al. 2007). The genes encoding NGR-TNFα-L were synthesized and subcloned into the pQE30 plasmid by Convenience Biology Inc. (Changzhou,
Na₂HPO₄, 137 mM NaCl, 2.68 mM KCl, 2 mM KH₂PO₄, dialyzed against phosphate buffered saline (PBS, 10 mM phosphate buffer (50 mM phosphate, pH 8.0, 300 mM NaCl, and 20 mM imidazole). Cells were broken by using a high-pressure homogenizer with 4 processes under 800 bar. The supernatants were collected by centrifugation at 8000 g at 4 °C for 30 min with repeated centrifugation at 15000 g at 4 °C for 15 min. The recombinant TNFα was purified using high-pressure liquid chromatography. The purified proteins were visualized with the enhanced chemiluminescence detection system (GE Healthcare, Uppsala, Sweden).

**Quantitative real-time polymerase chain reaction**

To examine gene transcription, an aliquot of the overnight cultured E. coli M15 cells was inoculated into 1 L of fresh LB. When the cells grew to log phase (A₆₀₀nm ≈ 0.8), IPTG (0.05 mM) was added into the cells, followed by collection at different time points (0–21 h). Total RNA was extracted using TRIzol® reagent (Thermo fisher scientific, MA, USA) according to the manufacturer’s instructions. RNA concentration was determined using a NanoDrop (Thermo fisher scientific, MA, USA). Reverse transcription of mRNA extracted from E. coli M15 cells into cDNA was performed using a high-capacity cDNA synthesis kit (Vazyme, Nanjing, China). Quantitative real-time PCR (qRT-PCR) was performed using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad, CA). The threshold cycles (Ct) were calculated by Bio-Rad CFX Manager. The transcription of recombinant genes was normalized using cysG and hcaT as reference genes (Zhou et al. 2011). To determine the mRNA stability after IPTG induction, the transcription of recombinant genes was arrested by the addition of rifampicin to a final concentration of 500 μg/mL into the cells at steady state of transcription (approximately 1 h postinduction). The cells were collected at different time points (0–8 min) after addition of rifampicin and immediately frozen in liquid nitrogen (Nouaille et al. 2017). Quantitative assays of the recombinant genes were performed by qRT-PCR. The decrease speed reflected the stability of the recombinant gene. Primers for qRT-PCR of hcaT (forward: 5'-GCTGCACGGGCTTTC TCACTCC-3', reverse: 5'-CCAACCACGGACGACCAACC-3'), cysG, (forward: 5'-TTGGCTGGCTGGTGTGATGC-3', reverse: 5'-ATCGGCTGACGGTGGATAGAAGC-3'), TNFα, (forward: 5'-AGATGGCATCACCACATCCAACA-3', reverse: 5'-AGCTGGTCTCCTCACCACCTTGTTG), or NGR-TNFα (forward: 5'-TCACCACGGATCCTTG-3', reverse: 5'-AGCTGGTCTCCTCACCACCTTGTTG-3') were synthesized by Songo Biotech (Shanghai, China).

**Size exclusion chromatography**

Size exclusion chromatography (SEC) was performed on an AKTA Pure with a Superdex G-75 XK10/30 column (GE Healthcare, Uppsala, Sweden). Proteins were separated on
the column at a constant flow rate of 0.5 ml/min, with PBS as the mobile phase and monitoring at 280 nM. The apparent molecular weight of proteins was estimated using molecular weight standards, including bovine serum albumin (Mr 67000), ovalbumin (Mr 43000), ribonuclease A (Mr 13700), aprotinin (Mr 6512), vitamin B12 (Mr 1355), and cytidine (Mr 234).

Mass spectrometry analysis

Proteins were denatured in UA buffer (8 M urea in 0.1 M Tris-HCl, pH 8.5) and were alkylated with 50 mM iodoacetamide (IAA) at room temperature for 1 h in the dark on a 10 KD centrifugal filter tube, followed by digestion with trypsin (1:50 (w/w)) in the ABC solution (50 mM ammonium bicarbonate) at 37 °C overnight. The tryptic peptides were desalted and lyophilized before resuspension in 0.1% formic acid (FA). A 500 ng of peptides was loaded and separated on a homemade micro-tip C18 column (75 μm × 200 mm, packed with ReproSil-Pur C18-AQ, 1.9 μm resin, Dr. Maisch Gmbh) over a 40-min gradient (buffer A, 0.1% FA; buffer B, 0.1% FA in ACN) on a nanoflow HPLC Easy-nLC 1200 system coupled to Orbitrap Fusion Lumos (Thermo Fisher Scientific, MA). The MS1 full scan was acquired at a resolution of 60,000, a scan range of 350–2000 m/z, AGC target 1e6, and maximum injection time of 50 ms. Precursor ions with charge from 2 + to 8 + were selected at a 1.6 m/z isolation window for MS/MS scans with a resolution of 30,000, AGC target 4e4, and maximum injection time of 54 ms, following stepped-HCD fragmentation. The raw data were analyzed by BioPharma Finder 4.0. The digestion of enzyme was set as trypsin, and two missed cleavage sites were allowed. The carbamidomethyl cysteine, disulfide bond, methionine oxidation, asparagine, and glutamine (NQ) deamidation were set as variable modifications. Mass error tolerance was set to 5 ppm. The peptide-spectrum matches (PSMs) of deamidated peptides were examined manually.

Cell culture and cytotoxicity assay

Murine fibroblasts (L929) purchased from American Type Culture Collection (ATCC) were cultured in Dulbecco’s-modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C in a 5% CO2 humidified atmosphere. To measure the cytotoxicity of proteins, L929 cells were inoculated into 96-well plates at 1 × 10^4 per well. After overnight culture, L929 cells were pretreated with 100 μL actinomycin-D (ACTD, 4 μg/mL) for 30 min prior to the addition of different concentrations of protein (Hoffmann et al. 2010). Surviving cells were measured using a cell counting kit-8 (CCK-8, Dojindo, Japan) 16 h later. PBS was used as a control. The viability of cells treated with protein was expressed as a percentage of PBS-treated cells. The live/dead backlight bacterial viability kit (Molecular robes, CA) was used to visualize dead and live cells. After treatment with proteins, cells were dually stained with the membrane-permeable SYTO 9 (15 μM) and the membrane-impermeable propidium iodide (PI, 2.5 μg/mL), followed by observation under a fluorescence microscope. The live and dead cells were illustrated as green and red, respectively.

Receptor binding assays

Biolayer interferometry was performed on the 2-Channel Entry-Level Octet System Octet K2 (Pall ForteBio LLC, CA). To examine the binding of TNFα proteins to TNF receptors, TNFR1-Fc or TNFR2-Fc (Sino Biological, Beijing, China) was first immobilized onto a protein A-coated biosensor. Subsequently, the biosensor was inserted into 50, 100, or 250 nM TNFα proteins dissolved in HBS-EP buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% Tween 20) for association and dissociation. The kinetic constants, including the association constant (ka) and dissociation constant (kd) and affinity (KD, KD = kd/ka), were calculated using data analysis software according to a 1:1 binding model. The CD13 expression in HT1080 cells was measured by flow cytometry (Kessler et al. 2018). To verify the interaction between NGR domain in fusion protein and CD13 on the cell surface, HT1080 cells were incubated with different concentration (100–500 nM) of FAM-labeled TNFα proteins at room temperature for 1 h prior to flow cytometry analysis. FAM labeling of protein was performed according to our previous work (Fan et al. 2019).

Tumor-bearing mice and treatment

Tumor-bearing mice were constructed by subcutaneous inoculation of 1 × 10^5 B16F1 cells into C57BL/6 female mice (6 weeks old). Mice were randomly divided into 6 groups (n = 7) on day 7 postinoculation, followed by treatment with TNFα proteins combined with or without doxorubicin (DOX). TNFα protein (1 μg/mouse) and DOX (3 mg/kg) were intravenously injected into tumor-bearing mice every other day for a total of five times. The mice in the control group were administered the same volume of PBS. Tumor grafts were measured every day, and the tumor volume was calculated by the formula: tumor volume = length × width^2 × 0.5. The survival rates and body weights of mice were recorded every day.

Statistical analysis

The results are presented as the means ± standard deviation (SD) from at least three independent experiments. One-way analysis of variance (ANOVA) for multiple comparisons was performed to analyze the differences among groups using
SPSS software version 13.0. The significance level was defined as $p < 0.05$.

**Results**

A single nucleotide mutation drastically increases the yield of NGR-TNFα in the *E. coli* M15-pQE30 expression system

As shown in Fig. 1a, the gene encoding NGR-TNFα-L differs from the gene encoding NGR-TNFα-V at a single nucleotide (C > G) within the initial codon of TNFα, which causes the substitution of leucine (L) at the start of TNFα by valine (V). To compare their difference in expression level, pQE30 plasmids containing the gene encoding NGR-TNFα-L (pQE30-NGR-TNFα-L) or NGR-TNFα-V (pQE30-NGR-TNFα-V) were transformed into *E. coli* M15 cells. Owing to the known similarity between colonies of *E. coli* M15, we randomly collected *E. coli* M15 cells containing an expression vector from a single colony for further protein expression analysis. As shown in Fig. 1b, SDS-PAGE of total proteins from bacteria indicated clear accumulation of a protein band with an apparent molecular weight of 18 KD in *E. coli* M15 cells containing pQE30-NGR-TNFα-V after induction with IPTG overnight. These induced proteins accounted for approximately 20% of total bacterial proteins predominantly existing as soluble proteins, but not insoluble inclusion bodies, in *E. coli* M15 cells. Further western blot with antibody against 6His-tag verified these induced proteins as NGR-TNFα-V, indicating that the gene encoding NGR-TNFα-V was highly expressed in the *E. coli* M15-pQE30 system. However, according to the total protein analysis and western blot, little accumulation of NGR-TNFα-L was observed in *E. coli* M15 cells containing pQE30-NGR-TNFα-L after induction under the same conditions (Fig. 1c), demonstrating that the efficacy of NGR-TNFα-L in inductive expression was much lower than that of NGR-TNFα-V in the same *E. coli* M15-pQE30 expression system. To validate this, inductive expression of the genes encoding NGR-TNFα-V and NGR-TNFα-L was further compared in *E. coli* M15 derived from three individual colonies. As shown in Fig. 2a and b, *E. coli* M15 cells derived from three individual colonies containing pQE30-NGR-TNFα-V produced NGR-TNFα-V as soluble proteins at a similarly high level. However, *E. coli* M15 cells derived from three individual colonies containing pQE30-NGR-TNFα-L only expressed a small amount of NGR-TNFα-L under the same conditions. Both NGR-TNFα-V and NGR-TNFα-L could be purified to homogeneity by Ni-NTA affinity chromatography (Fig. 2c and d). Further quantitative assays for the purified proteins demonstrated that the average yield of NGR-TNFα-V was over 20 mg/L, compared to 0.2 mg/L for that of NGR-TNFα-L, demonstrating that the yield of NGR-TNFα-V was approximately 100 times higher than that of NGR-TNFα-L in the *E. coli* M15-pQE30 system. These results indicated that the single C > G mutation in the gene encoding NGR-TNFα drastically increased the expression of NGR-TNFα protein.

**Fig. 1** Inducible expression of proteins in *E. coli* M15 cells containing the pQE30-NGR-TNFα plasmid. a Schematic diagram of the pQE30-NGR-TNFα expression plasmid and the single nucleotide mutation of C to G in the initial codon of TNFα resulting in a leucine (L) substitution with valine (V). b,c SDS-PAGE and western blot of the mutated (NGR-TNFα-V) (b) and native NGR-TNFα (NGR-TNFα-L) (c) in the presence of 2-ME. M, protein markers; lane 1, the total proteins of uninduced cells; lane 2, the total proteins of induced cells; lane 3, the soluble proteins of induced cells; lane 4, the insoluble proteins of induced cells.
As this single nucleotide mutation (C > G) occurred in the initial codon of TNFα, we further investigated the impact of this mutation on the inductive expression of TNFα. As shown in Fig. 3a, the gene encoding native TNFα with leucine at the start (TNFα-L) differs from that encoding mutated TNFα with valine at the start (TNFα-V) at a single nucleotide. These genes inserted into pQE30 were inductively expressed by IPTG in E. coli M15 (Fig. 3b). Similar to NGR-TNFα variants, both TNFα-V and TNFα-L were predominantly expressed as soluble proteins, which was easily purified to homogeneity by simple Ni-NTA affinity chromatography (Fig. 3c, d, and e). According to the quantitative assay for the purified soluble proteins, the yield of TNFα-V was approximately 2–3-fold (14.1 ± 2.3 mg/L vs 6.1 ± 2.1 mg/L) that of TNFα-L (Fig. 3f), indicating that the single nucleotide mutation improved the expression of TNFα in the E. coli M15-pQE30 system.
A single nucleotide mutation enhances the gene transcription of NGR-TNFα in the E. coli M15-pQE30 expression system

As nucleotide mutations might change gene expression by altering the transcriptional efficacy and stability of mRNA, the accumulation of transcripts for all TNFα variants in E. coli M15 cells was first analyzed by qRT-PCR. After induction by IPTG for different times, the E. coli M15 cells containing pQE30 expression vectors for TNFα variants were collected, followed by total RNA extraction for qRT-PCR. The expression level of TNFα variants in E. coli M15 cells collected at different times postinduction was normalized to that in cells collected at 0 h (before addition of IPTG), calculated as 1. As shown in Fig. 4a, the mRNA transcription level of NGR-TNFα-V increased 400–600 times after induction for 0.5–1 h and persisted at a high level (approximately 400-fold that at 0 h) to at least 21 h postinduction. However, NGR-TNFα-L transcripts did not clearly increase with time after induction by addition of IPTG. Similar to that of NGR-TNFα-V, accumulation of TNFα-V transcripts increased with time and peaked (120-fold that at 0 h) at 2 h postinduction, followed by a decrease to basic level at 21 h postinduction. After induction, accumulation of TNFα-L transcripts increased with time and peaked (80-fold that at 0 h) at 1 h postinduction, followed by a decrease to basic levels within 4 h (Fig. 4b). These results demonstrated that a single nucleotide mutation (C > G) significantly increased the transcriptional efficacy of NGR-TNFα in the E. coli M15-pQE30 expression system. mRNA stability is another impact factor for protein yield. Usually, mRNAs encoding most proteins are stable for a short time in E. coli, with a half-life less than 5 min (Esquerre et al. 2014). To assess mRNA stability, transcription machinery was blocked by the addition of rifampicin into E. coli once the transcription was at a steady state (approximately 1 h postinduction). As shown in Fig. 4c and d, no obvious difference was observed in the mRNA decrease after the addition of rifampicin between genes encoding all four
TNFα variants, indicating that the single nucleotide mutation (C > G) did not reduce the stability of genes encoding TNFα variants. Accordingly, the accumulation of these TNFα proteins in E. coli M15 cells was consistent with their gene expression profile. As shown in Fig. S1, NGR-TNFα-V was clearly produced at 0.5 h and accumulated more within 21 h postinduction. However, little NGR-TNFα-L accumulation was observed throughout the time-course analysis. The expression level of TNFα-L was also lower than that of TNFα-V. These results demonstrated that the single nucleotide mutation (C < G) increased the yields of the NGR-TNFα and TNFα predominantly by improving gene transcription.

A single nucleotide mutation-induced amino acid substitution does not reduce the receptor binding of NGR-TNFα

The NGR-TNFα-V purified by Ni-NTA affinity chromatography combined with SEC was visualized as a single protein band corresponding to its monomers on SDS-PAGE gel in the presence (Fig. 2d) or in the absence (Fig. 5a) of 2-ME. Accordingly, NGR-TNFα-V exhibits a single peak on the SEC column (Fig. 5b). Further mass spectrometry verified the purified protein as NGR-TNFα-V according to the N-terminal amino acid sequence (Fig. 5c). In contrast, NGR-TNFα-L was visualized as a single protein band on the gel of SDS-PAGE in the presence of 2-ME (Fig. 3e). In the absence of 2-ME, NGR-TNFα-L was illustrated as at least two protein bands corresponding to its monomer and dimer (Fig. 5a). Moreover, NGR-TNFα-L exhibited three protein peaks on the SEC column under naturing conditions (Fig. 5b). However, both TNFα-L and TNFα-V were showed as single protein peaks on the SEC column (Fig. S2a), suggesting that oligomerization of NGR-TNFα-L was induced by the fused NGR with cysteine residues that could form unexpected intermolecular disulfide bond. Notably, according to the SEC of proteins recovered by a single step of Ni-NTA affinity chromatography, the single nucleotide mutation-induced amino acid change from L to V in TNFα decreased the aggregation of NGR-TNFα (Fig. S2b).

NGR-TNFα can bind TNFR and CD13. Biolayer interferometry was used to evaluate the impact of the single amino
acid mutation on the receptor binding of NGR-TNFα. As shown in Table 1 and Fig. S3a, the affinity of TNFα-V for TNFR (0.3 ± 0.1 nM for TNFR1, 1.9 ± 0.1 nM for TNFR2) was similar to that of TNFα-L for TNFR (0.3 ± 0.1 nM for TNFR1, 2.1 ± 0.1 nM for TNFR2), indicating that the single amino acid mutation did not change the TNFR binding of TNFα. NGR-TNFα-V and NGR-TNFα-L showed comparable affinity for TNFR1 (0.5 ± 0.1 nM vs 0.7 ± 0.2 nM). Nevertheless, the affinity of NGR-TNFα-V for TNFR2 (2.5 ± 0.2 nM) was slightly higher than that (4.6 ± 0.3 nM) of NGR-TNFα-L for TNFR2 (Table 1 and Fig. S3b). The binding of TNFα proteins to CD13 was measured by cell binding analysis. As shown in Fig. 6a, CD13 was overexpressed in HT1080 cells. Both NGR-TNFα-V and NGR-TNFα-L exhibited a similar binding to HT1080 cells (Fig. 6b). However, TNFα-V and TNFα-L showed no obvious binding to HT1080 cells (Fig. 6c), indicating that the NGR motif in the fusion proteins preserved CD13-binding ability. These results demonstrated that the single nucleotide mutation-induced amino acid substitution had a little impact on the receptor binding of NGR-TNFα.

Table 1 Affinity of TNFα proteins for TNFα receptors

| Protein     | TNFR1 |        | TNFR1 |        |
|-------------|-------|--------|-------|--------|
|             | KD(M) | KD Error | KD(M) | KD Error |
| TNFα-L      | 3.088E-10 | 4.604E-11 | 2.103E-09 | 1.028E-10 |
| TNFα-V      | 3.258E-10 | 6.846E-11 | 1.862E-09 | 1.411E-10 |
| NGR-TNFα-L  | 7.409E-10 | 2.302E-10 | 4.634E-09 | 2.933E-10 |
| NGR-TNFα-V  | 5.261E-10 | 8.743E-11 | 2.452E-09 | 1.941E-10 |

Fig. 5 Polymerization analysis of NGR-TNFα variants. 

Polymerization analysis of NGR-TNFα variants. a Size exclusion chromatography of NGR-TNFα-V and NGR-TNFα-L was performed on Superdex G-75 XK10/30. The molecular weights of these proteins were calibrated with protein markers. b SDS-PAGE of NGR-TNFα-V and NGR-TNFα-L in the absence of 2-ME. To determine the stability of TNFα proteins, the cytotoxicity of these proteins was measured using L929 cells after the proteins were stored at 37 °C for different times.
A single nucleotide mutation-induced amino acid substitution does not alter the in vitro cytotoxicity or in vivo synergistic antitumor effect of NGR-TNFα.

Figure 7a and b showed that all the TNFα proteins exhibited weak cytotoxicity in L929 cells pretreated without ACTD. Quantitative assays demonstrated that these proteins only induced 20–40% cell death at high concentrations (10–100 ng/mL). However, these proteins induced over 90% cell death at a low concentration of 0.5 ng/mL in L929 cells pretreated with ACTD. In particular, the cytotoxicity of NGR-TNFα-V was comparable to that of NGR-TNFα-L in L929 cells pretreated with ACTD. In addition, TNFα-V was also similar to TNFα-L in vitro cell killing. Further live/dead cell visualization using SYTO9/PI dual staining verified the cytotoxicity of these TNFα proteins, demonstrating that the single amino acid substitution of L by V at the start of TNFα did not reduce the in vitro cytotoxicity of the native TNFα proteins. Stability assays demonstrated that all TNFα proteins displayed comparable activity without evident decline within 5 days (Fig. 7c), demonstrating that changing the amino acid from L to V at the start of TNFα had little impact on the stability of NGR-TNFα.
Low-dose NGR-TNFα exerts synergistic antitumor effects with DOX (Corti et al. 2013). To evaluate the impact of the single amino acid substitution on the in vivo biological activity of NGR-TNFα, the antitumor effects of NGR-TNFα-V and NGR-TNFα-L combined with DOX were compared in mice bearing B16F1 melanoma. As shown in Fig. 8, DOX exhibited antitumor effects in mice bearing B16F1 melanoma. Nevertheless, NGR-TNFα-V and NGR-TNFα-L alone only slightly suppressed tumor growth when compared to PBS. However, coadministration with either NGR-TNFα-V or NGR-TNFα-L significantly ($P < 0.05$) enhanced the antitumor effects of DOX. At the end of the observation, the average tumor volumes in NGR-TNFα-V/DOX-treated mice and NGR-TNFα-L/DOX-treated mice were 44.7 ± 20.4 mm$^3$ and 90.6 ± 31.6 mm$^3$, respectively, compared to 176 ± 59.8 mm$^3$ for that of DOX-treated mice. The similarity between NGR-TNFα-V and NGR-TNFα-L in synergistic antitumor effects with DOX indicated that the single nucleotide mutation-induced amino acid substitution in TNFα did not reduce the biological activity of NGR-TNFα.

**Discussion**

Although its systemic toxicity was reported a long time ago, TNFα, the most potent immune stimulator is still attractive for the development of novel anticancer therapeutics. Tumor-targeted delivery is an effective way to reduce the systemic
toxicity of TNFα. In fact, the tumor-homing NGR-TNFα exerted promising antitumor effects with definitely improved biosafety, which triggered extensive interest in developing tumor-homing TNFα as a novel anticancer drug (Gregorc et al. 2009; Johansson et al. 2012). In our previous work, a novel tumor-homing TNFα variant, Z-TNFα, was produced with high yield using the E. coli M15-pQE30 system (Fan et al. 2019). To further compare Z-TNFα and NGR-TNFα, we attempted to produce NGR-TNFα using the same E. coli M15-pQE30 system. Surprisingly, we found that the native NGR-TNFα (NGR-TNFα-L) was expressed at a low level (~0.2 mg/L) in this system. However, the expression level of NGR-TNFα-V, which differs from NGR-TNFα-L at a single amino acid at the start of TNFα, was approximately 100 times higher than that of NGR-TNFα-L (Fig. 2). Further investigation revealed that the yield of TNFα-V, which differs from TNFα-L at a single amino acid, was approximately 2–3 times higher (14.1 ± 2.3 mg/L vs 6.1 ± 2.1 mg/L) than that of TNFα-L (Fig. 2). These results indicated that the single nucleotide mutation-induced substitution of leucine (L) with valine (V) increased the expression of NGR-TNFα and TNFα.

Protein expression in E. coli might be affected by multiple factors, including the vector, host cell, culture parameters, coexpressed genes, and gene sequence (Gopal and Kumar 2013). In the same expression system and culture parameters, protein expression is primarily influenced by the protein solubility or gene sequence. Usually, the solubility of proteins can affect the expression level of genes in host cells. It was found that TNFα was predominantly expressed as insoluble inclusion bodies in E. coli BL21 containing the pET plasmid with a strong T7 promoter. And it was noted that accumulation of inclusion bodies provided a negative feedback to the expression of TNFα (Binepal et al. 2012). In our experiment, TNFα and NGR-TNFα variants were predominantly expressed as soluble proteins in E. coli M15 containing the pQE30 plasmid with a weaker T5 promoter (Fig. 1 and 3), suggesting that the variation in expression of these TNFα proteins might not be attributed to the inclusion body accumulation-mediated negative feedback.

In addition to the protein properties, the sequence of the gene is closely related to its expression level in host cells. In the expression plasmid, elements, including the promoter, 5′ UTR, and initial codons of the recombinant gene, were the major impact factors for gene expression (Francis and Page 2010; Jia and Jeon 2016). In this paper, all TNFα and NGR-TNFα variants were cloned into the pQE30 plasmid. These expression plasmids containing TNFα or NGR-TNFα variants were only different (C > G) in the initial codon of the TNFα gene (Fig. 1a and 3a). The nucleotide mutation from C to G did not produce a rare codon (CUC to GUC) and had no

---

**Fig. 8** In vivo antitumor effect of NGR-TNFα proteins combined with DOX. From day 7 postinoculation of B16F1 cells, TNFα protein (1 μg/mouse) and DOX (3 mg/kg) were intravenously injected into mice every other day for a total of five injections. The perspective tumor growth curves were indicated.
influence on the translation of TNFα variants in *E. coli*. However, G at the 5′-end of a gene is more potent than C in that region in terms of impact on gene expression (Boel et al. 2016). Consequently, the variation of TNFα and NGR-TNFα variants in yield might be attributed to the alternation in transcription induced by the change of C to G in the initial codon of TNFα. In fact, qRT-PCR demonstrated that the transcription of NGR-TNFα-V with G in the initial codon of TNFα was higher than that of NGR-TNFα-L with C in the initial codon. Similarly, the transcription of TNFα-V was also higher than that of TNFα-L (Fig. 4a and b). It is known that transcription and translation are coupled in the pQE30 plasmid with T5 promoter, which may affect transcription levels when the nucleotide mutation occurs at the 5′-end of mRNA, presumably by premature transcription termination through the formation of secondary structures (Bhattacharyya et al. 2018; Stueber et al. 1984). The fact that the mutation of C to G in the initial codon of TNFα increased the yield of TNFα and NGR-TNFα variants by predominantly improving transcription in the *E. coli* M15-pQ30 system is consistent with the coupled transcription and translation in pQE30.

In the *E. coli* M15-pQ30 expression system, the yield of TNFα-L (6.1 ± 2.1 mg/L) was higher than that of NGR-TNFα-L (0.2 mg/L), indicating that the N-terminal fusion of NGR peptide reduced the expression of TNFα-L in this system. However, both TNFα-V and NGR-TNFα-V were highly expressed in the same expression system, demonstrating that fusion of the NGR peptide to the N-terminus of TNFα-V had little impact on the yield of the fusion protein. Importantly, NGR-TNFα-V was similar to NGR-TNFα-L in receptor-binding (Fig. 6), in vitro cytotoxicity (Fig. 7), and in vivo antitumor effect (Fig. 8), suggesting that TNFα-V might also be used to prepare novel tumor-homing TNFα variants. Taken together, our results demonstrated that a single nucleotide C > G mutation in the initial codon of TNFα drastically (~100 times) increased the expression of NGR-TNFα in *E. coli* M15-pQ30 system by improving transcription. The single nucleotide C > G mutation causing a substitution of leucine with valine at the start of TNFα had little impact on the biological activity of NGR-TNFα, indicating that TNFα with valine substitution at the start might be used to prepare novel tumor-homing TNFα variant, especially when the native TNFα-based variant is expressed at an extremely low level in *E. coli*.

### Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00253-021-11136-x.

### Acknowledgment

The authors thank Xijing Yang (Animal Center of West China Hospital, Sichuan University) for her help in animal experiments.

### Author contributions

CJ and YH performed most experiments. FYR and SQX contributed to animal experiments. LZ and TZ purified proteins. FJ and LSF cultured cells. JYM extracted RNA. CJQ and LXF conceived this project. LXF, CJ, and YH wrote the paper, and all authors read and approved the manuscript.

### Funding

This study was funded by the National Natural Science Fund of China (81573336), the Key R&D Program of Sichuan Province (2020YFS0072), the Special Project for COVID-19 of West China Hospital, Sichuan University (HX-2019-nCoV-018), and the “13.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University” (ZYGD18014).

### Data availability

Data and materials will be made available on reasonable request.

### Compliance with ethical standards

#### Conflict of interest

The authors declare that they have no conflict of interest.

#### Ethical approval

All applicable institutional guidelines for the care and use of animals were followed.

### References

Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361–371. https://doi.org/10.1038/nrc2628

Bhattacharyya S, Jacobs WM, Adkar BV, Yan J, Zhang W, Shakhnovich EI (2018) Accessibility of the Shine-dalgarno sequence dictates N-terminal codon bias in *E. coli*. Mol Cell 70(5):894–905 e5. https://doi.org/10.1016/j.molcel.2018.05.008

Binepal G, Ranjan RK, Rajagopal K (2012) Expression of synthetic human tumor necrosis factor is toxic to *Escherichia coli*. Gene 493(1):155–160. https://doi.org/10.1016/j.gene.2011.11.025

Boel G, Letso R, Neely H, Price WN, Wong KH, Su M, Luff J, Valecha M, Everett JK, Acton TB, Xiao R, Montelonne GT, Aalberts DP, Hunt JF (2016) Codon influence on protein expression in *E. coli* correlates with mRNA levels. Nature 529(7586):358–363. https://doi.org/10.1038/nature16509

Corti A, Cumis F, Rossoni G, Marcucci F, Gregore V (2013) Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example. BioDrugs 27(6):591–603. https://doi.org/10.1007/s12880-013-0048-z

Cumis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A (2000) Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18(11):1185–1190. https://doi.org/10.1038/81183

Cumis F, Gasparri A, Sacchi A, Longhi R, Corti A (2004) Coupling tumor necrosis factor-α with αV integrin ligands improves its anti-neoplastic activity. Cancer Res 64:565–571

Esquerre T, Laguerre S, Turlan C, Caropousi AJ, Girbal L, Caoaign-Bousquet M (2014) Dual role of transcription and transcript stability in the regulation of gene expression in *Escherichia coli* cells cultured on glucose at different growth rates. Nucleic Acids Res 42(4):1555–1571. https://doi.org/10.1093/nar/gkt1150

Fan X, Tao Z, Yang H, Shi Q, Wang H, Jia D, Wan L, Zhang J, Cheng J, Lu X (2019) Modulation of pericytes by a fusion protein comprising of a PDGF-Rbeta-antagonistic affibody and TNFα-ligase induces tumor vessel normalization and improves chemotherapy. J Control Release 302:63–78. https://doi.org/10.1016/j.jconrel.2019.03.018

Francis DM, Page R (2010) Strategies to optimize protein expression in *E. coli*. Curr Protocols Protein Sci Chapter 5:Unit 5:24:1–29. https://doi.org/10.1002/0471140864.ps0524s61
Gopal GJ, Kumar A (2013) Strategies for the production of recombinant protein in *Escherichia coli*. Protein J 32(6):419–425. https://doi.org/10.1007/s10930-013-9502-5

Gregorio V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer-Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM (2009) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 101(2):219–224. https://doi.org/10.1038/sj.bjc.6605162

Ho YJ, Chu SW, Liao EC, Fan CH, Chan HL, Wei KC, Yeh CK (2019) Normalization of tumor vasculature by oxygen microbubbles with ultrasound. Theranostics 9(24):7370–7383. https://doi.org/10.7150/thno.37750

Hoffmann A, Müller MQ, Gloser M, Sinz A, Rudolph R, Pfeifer S (2010) Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Protein Expr Purif 72(2):238–243

Hong S, Zheng DW, Zhang C, Huang QX, Cheng SX, Zhang XZ (2020) Vascular disrupting agent induced aggregation of gold nanoparticles for photothermally enhanced tumor vessel disruption. Sci Adv 6(23):eabb0020. https://doi.org/10.1126/sciadv.abb0020

Jia B, Jeon CO (2016) High-throughput recombinant protein expression in *Escherichia coli*: current status and future perspectives. Open Biol 6(8):160196. https://doi.org/10.1098/rsob.160196

Johansson A, Hamzah J, Payne CJ, Ganss R (2018) Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 18(3):195–203. https://doi.org/10.1038/s41577-017-145

Jakob K, Hohenberger P (2016) Role of isolated limb perfusion with recombinant human TNF-alpha by SUMOFusion system–high yields from shake-flask culture. Protein Expr Purif 72(2):2384–2343

Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harnach S, Stalmann U, Schmidt HL, Gosheger G, Hardes J, Andreou D, Dreischläück J, Lenz G, Wardelmann E, Mesters RM, Schwöppe C, Berdel WE, Hartmann W, Schliemann C (2018) Aminopeptidase N (CD13): expression, prognostic impact, and use as therapeutic target for tissue factor induced tumor vascular infarction in soft tissue sarcoma. Transl Oncol 11(6):1271–1282

Lugano R, Ramachandran M, Dimberg A (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77(9):1745–1770. https://doi.org/10.1007/s00018-019-03351-7

Nouaille S, Mondeil S, Finoux AL, Moulis C, Girbal L, Cocaign-Bousquet M (2017) The stability of an mRNA is influenced by its concentration: a potential physical mechanism to regulate gene expression. Nucleic Acids Res 45(20):11711–11724. https://doi.org/10.1093/nar/gkx781

Park JS, Kim IK, Han S, Park I, Kim C, Bae J, Oh SJ, Lee S, Kim JH, Woo DC, He Y, Augustin HG, Kim I, Lee D, Koh YG (2017) Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell 31(1):157–158. https://doi.org/10.1016/j.ccell.2016.12.009

Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 37(1):63–74. https://doi.org/10.1016/j.ctrv.2010.05.001

Stueber D, Ibrahimi I, Cutler D, Dobberstein B, Bujard H (1984) A novel transcription-translation system: accurate and efficient synthesis of single proteins from cloned DNA sequences. EMBO J 3(13):3143–3148

Viallard C, Larrivee B (2017) Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 20(4):409–426. https://doi.org/10.1007/s10456-017-9562-9

Yang H, Wan L, Li X, Cai H, Chen L, Li S, Li Y, Cheng J, Lu X (2007) High level expression of his-tagged colicin 5 in *E. coli* and characterization of its narrow-spectrum bactericidal activity and pore-forming action. Protein Expr Purif 54(2):309–317. https://doi.org/10.1016/j.pep.2007.03.006

Yehya AHS, Asif M, Petersen SH, Subramaniam AV, Kono K, Majid A, Oon CE (2018) Angiogenesis: managing the culprits behind tumorigenesis and metastasis. Medicina (Kaunas) 54(1):8. https://doi.org/10.3390/medicine54010008

Yuan CE, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, Howell SB (2009) Recombinant CPE fused to tumor necrosis factor alpha and melphalan in locally advanced extremity soft tissue sarcoma. Cancer 122(17):2624–2632. https://doi.org/10.1002/cncr.29991

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.